LY3849891
/ Eli Lilly, Novo Nordisk
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
December 03, 2024
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=176 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Dec 2025 ➔ Sep 2026 | Trial primary completion date: Dec 2025 ➔ Sep 2026
Trial completion date • Trial primary completion date • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease • PNPLA3
June 26, 2024
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=176 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Nov 2024 ➔ Dec 2025 | Trial primary completion date: Nov 2024 ➔ Dec 2025
Trial completion date • Trial primary completion date • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease • PNPLA3
October 23, 2023
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=176 | Recruiting | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Recruiting
Enrollment open • Hepatology • Non-alcoholic Fatty Liver Disease • PNPLA3
October 11, 2023
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=176 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting
Enrollment closed • Hepatology • Non-alcoholic Fatty Liver Disease • PNPLA3
June 23, 2022
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=176 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatology • Non-alcoholic Fatty Liver Disease
May 27, 2022
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
(clinicaltrials.gov)
- P1 | N=176 | Not yet recruiting | Sponsor: Eli Lilly and Company
New P1 trial • Hepatology • Non-alcoholic Fatty Liver Disease
1 to 6
Of
6
Go to page
1